Drug Approval | July 05, 2022
Novavax aims COVID vaccine on Omicron in Q4
The vaccine is under FDA review
The vaccine is under FDA review
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
